AUTHOR=Lieber Attila , Makai Attila , Orosz Zsuzsanna , Kardos Tamás , Isaac Susil Joe , Tornyi Ilona , Bittner Nóra 

TITLE=The role of immunotherapy in early-stage and metastatic NSCLC

JOURNAL=Pathology and Oncology Research

VOLUME=Volume 30 - 2024

YEAR=2024

URL=https://www.por-journal.com/journals/pathology-and-oncology-research/articles/10.3389/pore.2024.1611713

DOI=10.3389/pore.2024.1611713

ISSN=1532-2807

ABSTRACT=In the past decade we have seen new advances and by that remarkable progress in therapeutic possibilities of non-small cell lung cancer (NSCLC). Among cytostatic therapies with new approaches in molecularly targeted therapies, we see new development in a wide range of applications for immunotherapies. In this review we discuss the new potential modalities for the use of immune checkpoint inhibitors (ICIs) in frontline, includingearly stage (perioperative) and metastatic setting. The perioperative use of ICIs in both neoadjuvant and adjuvant setting may show benefit for patients. In early-stage NSCLC (from stage IIB and above) multimodal approach is recommended as gold standard for the treatment. After surgical resection platinum-based adjuvant chemotherapy was the standard of care for many years. Based on the benefit in disease free survival, the approval of adjuvant atezolizumab and adjuvant pembrolizumab were a significant breakthrough. In metastatic setting, the use of immune checkpoint inhibitor with chemotherapy, regardless of PD-L1 expression or ICI alone (PD-L1 expression equal or greater than 50%) improves overall survival and progression-free survival as well.